Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Vij

Showing results (161-170 of 283) with videos related to

Pageof 29
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 30, 2017
Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell TransplantationYi-Shan Lee, Jingxia Liu, Kristine A Fricano, et al.
Journal of Translational Medicine|February 2, 2015
Personalization of cancer treatment using predictive simulationNicole A Doudican, Ansu Kumar, Neeraj Kumar Singh, et al.
Annals of Hematology|August 3, 2017
Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control studyArtur Jurczyszyn, Alessandro Gozzetti, Joanna Gdula-Argasińska, et al.
Leukemia|May 16, 2020
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myelomaJoseph Mikhael, Joshua Richter, Ravi Vij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong SurvivalFrancesca Fontana, Michael J Scott, John S Allen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2022
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple MyelomaAnita D'Souza, Nina Shah, Cesar Rodriguez, et al.
Iscience|January 23, 2025
Germline predisposition in multiple myelomaFernanda Martins Rodrigues, Jagoda Jasielec, Melody Perpich, et al.
Plos One|May 29, 2015
Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell TypesSarah R Amend, William C Wilson, Liang Chu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 25, 2022
First-in-Humans Evaluation of Safety and Dosimetry of <sup>64</sup>Cu-LLP2A for PET ImagingRichard Laforest, Anchal Ghai, Tyler J Fraum, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 15, 2013
Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimenShivaprasad Manjappa, Pavan Kumar Bhamidipati, Keith E Stokerl-Goldstein, et al.
Pageof 29

Showing results (161-170 of 283) with videos related to

Sort By:
Pageof 29
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 30, 2017
Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell TransplantationYi-Shan Lee, Jingxia Liu, Kristine A Fricano, et al.
Journal of Translational Medicine|February 2, 2015
Personalization of cancer treatment using predictive simulationNicole A Doudican, Ansu Kumar, Neeraj Kumar Singh, et al.
Annals of Hematology|August 3, 2017
Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control studyArtur Jurczyszyn, Alessandro Gozzetti, Joanna Gdula-Argasińska, et al.
Leukemia|May 16, 2020
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myelomaJoseph Mikhael, Joshua Richter, Ravi Vij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong SurvivalFrancesca Fontana, Michael J Scott, John S Allen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2022
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple MyelomaAnita D'Souza, Nina Shah, Cesar Rodriguez, et al.
Iscience|January 23, 2025
Germline predisposition in multiple myelomaFernanda Martins Rodrigues, Jagoda Jasielec, Melody Perpich, et al.
Plos One|May 29, 2015
Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell TypesSarah R Amend, William C Wilson, Liang Chu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 25, 2022
First-in-Humans Evaluation of Safety and Dosimetry of <sup>64</sup>Cu-LLP2A for PET ImagingRichard Laforest, Anchal Ghai, Tyler J Fraum, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 15, 2013
Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimenShivaprasad Manjappa, Pavan Kumar Bhamidipati, Keith E Stokerl-Goldstein, et al.
Pageof 29